ClinicalTrials.gg
CompletedNCT00312104Updated Jan 27, 2017

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes

A Phase 3 interventional study of insulin detemir and insulin glargine in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 46 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Detemir · Diabetes Mellitus, Type 1.

Enrollment
13th of 35
325 · median 83
Started
2002
with 3 others
Phase 3
18 of 35
none open now
Registered
5th of 35
by date
Lead sponsor
25 of 35
Novo Nordisk A/S

Among the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1, this one is the 13th largest by enrollment, is one of 4 that started in 2002, is one of 18 in phase 3, and was the 5th registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Detemir

Insulin Detemir: first FDA approval 2005 (LEVEMIR FLEXTOUCH), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 as a file.
02

Study summary

The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime insulin aspart. The trial involves patients with Type 1 Diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 325 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes for at least 12 months
  • Current daily insulin dose of more than 1.4 IU/kg
  • lesser than or equal to 35 kg/m2
  • greater than 7.5% and less than or equal to 12.0%
  • In Austria, age more than 19 years

Exclusion criteria

Exclusion Criteria:

  • Proliferate retinopathy or maculopathy
  • Recurrent major hypoglycaemia
  • Any condition or disease such as uncontrolled hypertension or AIDS/ that rule out trial participation according to the judgement of the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
325 participants (actual)
07

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: after 26 weeks of treatment

Secondary outcomes

  1. Adverse events

  2. Body weight

  3. Blood glucose

  4. Hypoglycaemia

08

Study locations

46 sites
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, 1090, Austria
  • Novo Nordisk Investigational Site
    Wien, A 1160, Austria
  • Novo Nordisk Investigational Site
    Wien, A-1130, Austria
  • Novo Nordisk Investigational Site
    Bad Kreuznach, 55545, Germany
  • Novo Nordisk Investigational Site
    Bad Mergentheim, 97980, Germany
  • Novo Nordisk Investigational Site
    Bad Neuenahr-Ahrweiler, 53474, Germany
  • Novo Nordisk Investigational Site
    Berlin, 10789, Germany
  • Novo Nordisk Investigational Site
    Diez, 65582, Germany
  • Novo Nordisk Investigational Site
    Erlangen, 91052, Germany
  • Novo Nordisk Investigational Site
    Essen, 45138, Germany
  • Novo Nordisk Investigational Site
    Flensburg, 24939, Germany
  • Novo Nordisk Investigational Site
    Frankfurt, 60590, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Genthin, 39307, Germany
  • Novo Nordisk Investigational Site
    Halle, 06120, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 20251, Germany
  • Novo Nordisk Investigational Site
    Hannover, 30171, Germany
  • Novo Nordisk Investigational Site
    Heidelberg, 69115, Germany
  • Novo Nordisk Investigational Site
    Hennigsdorf, 16761, Germany
  • Novo Nordisk Investigational Site
    Hünxe, 46569, Germany
  • Novo Nordisk Investigational Site
    Jena, 07743, Germany
  • Novo Nordisk Investigational Site
    Kiel, 24105, Germany
  • Novo Nordisk Investigational Site
    Landau, 76829, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    Marl, 45770, Germany
  • Novo Nordisk Investigational Site
    Mönchengladbach, 41061, Germany
  • Novo Nordisk Investigational Site
    Neunkirchen, 66538, Germany
  • Novo Nordisk Investigational Site
    Neuss, 41460, Germany
  • Novo Nordisk Investigational Site
    Northeim, 37154, Germany
  • Novo Nordisk Investigational Site
    Nürnberg, 90402, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    Rheda-Wiedenbrück, 33378, Germany
  • Novo Nordisk Investigational Site
    Saarbrücken, 66121, Germany
  • Novo Nordisk Investigational Site
    Saarlouis, 66740, Germany
  • Novo Nordisk Investigational Site
    Schwabenheim, 55270, Germany
  • Novo Nordisk Investigational Site
    Schwerin, 19049, Germany
  • Novo Nordisk Investigational Site
    Schönebeck, 39218, Germany
  • Novo Nordisk Investigational Site
    Völklingen, 66333, Germany
  • Novo Nordisk Investigational Site
    Wiesbaden, 65183, Germany
  • Novo Nordisk Investigational Site
    Würzburg, 97072, Germany
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 2193, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4091, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape 7130, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape 7925, South Africa
09

References and documents

Publications

  • Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA, Robertson LI. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med. 2007 Jun;24(6):635-42. doi: 10.1111/j.1464-5491.2007.02113.x. Epub 2007 Mar 22. PubMed 17381500 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2002, a primary completion of Mar 2003 and a completion of Mar 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2006
First posted
Apr 7, 2006
Start
Apr 2002
Primary completionActual
Mar 2003
CompletionActual
Mar 2003
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00312104
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 7, 2006
Start date
Apr 2002
Primary completion
Mar 2003
Completion
Mar 2003
Last update
Jan 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Detemir · Insulin Glargine

Start the discussion